Just what we don't need. Yet another study claiming that Advil plus Tylenol outperforms Vicodin. Lost in the sauce is that ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with ...

Results in The Journal of American Dental Association showed the non-opioid combination provided superior pain relief during ...

Inservice education prepared pharmacists for discussions with physicians about opioid analgesics. Phase 3 centered on an automatic interchange from meperidine to an equianalgesic dose of morphine ...

Tonix Pharmaceuticals (NASDAQ: TNXP) has appointed Gary Ainsworth as Vice President, market Access, as the company prepares for the potential FDA approval of TNX-102 SL, a non-opioid analgesic for ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...